SQZ Biotechnologies Company (SQZB)
| Previous Close | 0.0499 |
| Open | 0.0465 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0499 - 0.0499 |
| 52 Week Range | 0.0100 - 0.6540 |
| Volume | |
| Avg. Volume | 167,872 |
| Market Cap | 1.472M |
| Beta (5Y Monthly) | 1.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4300 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.00 |
Business WireAsset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
WATERTOWN, Mass., February 29, 2024--SQZ Biotechnologies Company (OTC: SQZB) (the "Company" or "SQZ") today announced the results for the proposals considered and voted upon by its shareholders at its special meeting on February 29, 2024 (the "Special Meeting"). The Company reported that all of the proposals submitted to its shareholders in connection with the previously announced asset sale pursuant to that certain Asset Purchase Agreement (the "Purchase Agreement"), dated December 21, 2023, en
Business WireSQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.WATERTOWN, Mass., November 08, 2023--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial results and recent portfolio updates.
Business WireSQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
WATERTOWN, Mass., November 03, 2023--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023.
